Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
News|Articles|September 30, 2025
Key pediatric FDA decisions to watch for in Q4 2025
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Morgan Ebert, Executive Editor
From another potential treatment for pediatric atopic dermatitis, to STI therapy for uncomplicated urogenital gonorrhea, take a look ahead at key PDUFA dates in Q4.
Advertisement
Advertisement
The fourth quarter of 2025 has all but arrived, and with it, several key potential approvals from the FDA for the pediatric population. From treatments for achondroplasia to
Related to this article
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Advertisement
Advertisement